Development of a novel universal (cross-protective) vaccine technology for influenza viruses

开发新型流感病毒通用（交叉保护）疫苗技术

• 批准号: 402674
• 负责人: Agrawal Babita
• 金额: $ 26.75万
• 依托单位: University of Alberta
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-03-01 至 2022-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=402674&lang=en
• 关键词: Influenza Vaccine; Product Commercialization; Universal Influenza Vaccine

Influenza viruses represent a public health threat worldwide, infecting 5-20% of the population each year, causing annual epidemics leading to ~500,000 deaths every year. Besides seasonal influenza, intermittent pandemic influenza poses the real threat of

流感病毒代表了全球范围内的公共卫生威胁，每年感染5-20%的人口，每年引起流行病，导致约500，000人死亡。除季节性流感外，间歇性大流行性流感构成了真实的威胁，